ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.

Ondrej Fiala et al.PubMed ↗Publisher ↗

No numbers read from the abstract.